{"id":"W3112144762","doi":"10.1093/neuonc/noaa215.211","title":"CTNI-45. A PHASE 1B/2 CLINICAL STUDY OF NAPABUCASIN IN COMBINATION WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH RECURRENT OR PROGRESSED GLIOBLASTOMA MULTIFORME (GBM)","year":2020,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary","funders":"","keywords":"Temozolomide; Medicine; Internal medicine; Tolerability; Phases of clinical research; Adverse effect; Oncology; Surgery; Gastroenterology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001081398,0.001325418,0.001259829,0.0004266158,0.0003298834,0.0006321917,0.0006910313,0.0007419937,0.002843231],"category_scores_gemma":[0.0005325226,0.0005685079,0.0008706386,0.0003458971,0.0006260247,0.0005192012,0.0002742101,0.002212078,0.0006330741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008777965,"about_ca_system_score_gemma":0.001797102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002522103,"about_ca_topic_score_gemma":0.007882861,"domain_scores_codex":[0.9997043,0.0001383232,0.00001545406,0.00004821371,0.00002672897,0.00006690313],"domain_scores_gemma":[0.9997247,0.00002281046,0.00004743859,0.00001964126,0.00001919539,0.0001662293],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5141149,0.1019978,0.006425568,0.001256584,0.001563211,0.000418316,0.0004850801,0.003551395,0.1961859,0.0007491988,0.009434664,0.1638174],"study_design_scores_gemma":[0.4440739,0.5203029,0.01445564,0.00005843621,0.0005818214,0.000372276,0.0000588054,0.00211067,0.01223122,0.0001905729,0.00551485,0.00004896498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878162,0.003105997,0.0007841673,0.0004350255,0.0001528718,0.003533151,0.001291468,0.0001798011,0.002701511],"genre_scores_gemma":[0.9859731,0.002632892,0.002624695,0.000685646,0.0001230463,0.00240399,0.002602032,0.00003531705,0.002919324],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002843231,"threshold_uncertainty_score":0.00951153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1544762611913571,"score_gpt":0.4754712240521156,"score_spread":0.3209949628607585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}